Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations.

Summary

Across mouse, cell, and human epithelium, IL-6 was identified as a trained, central driver of asthma exacerbations. Neutralizing IL‑6 prevented experimental exacerbations, and IL6 hypomethylation in patient airway epithelium predicted higher expression and future exacerbations.

Key Findings

• Intranasal anti‑IL‑6 completely prevented poly(I:C)-induced exacerbations in allergic asthma mice.
• Repeated poly(I:C) or RV16 exposure ‘trained’ IL6 upregulation in human bronchial epithelial cells.
• IL6 hypomethylation in airway epithelium associated with higher IL6 expression and future exacerbations in patient cohorts.

Clinical Implications

IL6 methylation and epithelial IL‑6 expression may stratify exacerbation-prone asthma, and targeted IL‑6 blockade or epithelial-focused interventions could prevent virus-triggered exacerbations.

Limitations

• Poly(I:C) models mimic viral PAMPs but may not fully recapitulate diverse clinical viruses and comorbidities.
• Human cohort sizes are moderate and require broader validation; therapeutic IL‑6 targeting not yet tested clinically for exacerbation prevention.

Future Directions

Validate IL6 methylation/IL‑6 expression as predictive biomarkers in multicenter cohorts and test intranasal/airway-targeted IL‑6 blockade or epigenetic modulators to prevent viral-triggered exacerbations.